Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Prognostic Role of the Pectoralis Musculature in Patients with COVID-19. A Multicenter Study

Alexey Surov, MD, Hakan Kardas, MD, Giulia Besutti, MD, Massimo Pellegrini, MD, Marta Ottone, MD, Mehmet Ruhi Onur, MD, Firat Atak, MD, Ahmet Gurkan Erdemir, MD, Elif Hocaoglu, MD, Ömer Yıldız, MD, Ercan Inci, MD, Eda Cingöz, MD, Mehmet Cingöz, MD, Memduh Dursun, MD, İnan Korkmaz, MD, Çağrı Orhan, MD, Alexandra Strobel, MD, Andreas Wienke, MD, Maciej Pech, MD

Rationale and Objectives: To evaluate the impact of low skeletal muscle mass in patients with COVID-19 on relevant outcomes like 30-day mortality, need for intubation and need for intensive care unit admission.

Materials and Methods: For this study, data from six centers were acquired. The acquired sample comprises 1138 patients. There were 547 women (48.1%) and 591 men (51.9%) with a mean age of 54.5 ± 18.8 years; median age, 55 years; range, 18–84 years). In every case, thoracic CT without intravenous application of contrast medium was performed. The following parameters of the pectoralis muscles were estimated: muscle area as a sum of the bilateral areas of the pectoralis major and minor muscles, muscle density, muscle index (PMI) (pectoralis muscle area divided by the patient’s body height square) as a ratio pectoralis major and minor muscles divided by the patient’s body height², and muscle gauge as PMI x muscle density.

Results: Overall, 220 patients (19.33%) were admitted to the intensive care unit. In 171 patients (15.03%), mechanical lung ventilation was performed. Finally, 154 patients (13.53%) died within the observation time of 30-day. All investigated parameters of pectoralis muscle were lower in the patients with unfavorable courses of Covid-19. All pectoralis muscle parameters were associated with 30-day mortality in multivariate analyses adjusted for age and sex: pectoralis muscle area, HR = 0.93 CI 95% (0.91–0.95) p < 0.001; pectoralis muscle density, HR = 0.94 CI 95% (0.93–0.96) p < 0.001; pectoralis muscle index, HR = 0.79 CI 95% (0.75–0.85) p < 0.001, pectoralis muscle gauge, HR = 0.995 CI 95% (0.99 0.96) p < 0.001.

Conclusion: in COVID-19, survivors have larger areas and higher index, gauge and density of the pectoralis muscles in comparison to nonsurvivors. However, the analyzed muscle parameters cannot be used for prediction of disease courses.

Key Words: COVID-19; sarcopenia; survival.

© 2022 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.
Also, extrapulmonary findings play an important role in COVID-19 (8). It has been shown that pleural effusion, pericardial effusion and mediastinal lymphadenopathy can be used as predictors of severe course of COVID-19 (6,8). In fact, pleural effusion and coronary calcifications are strong predictors of mortality in COVID-19, odds ratio (OR) = 4.6 (95% CI 2.97–7.12), \( p < 0.00001 \), and OR = 2.68 (95% CI 1.78–4.04), \( p < 0.00001 \), respectively (8).

Similarly, low skeletal muscle mass (LSMM) measured on CT can also predict unfavourable courses of COVID-19 (9).

The purpose of the present multi-center study was to evaluate the impact of LSMM in COVID-19 patients on relevant outcomes like 30-day mortality, need for intubation and need for intensive care.

**METHODS**

**Data Acquisition and Patients**

This retrospective study was approved by our institutional review board (Medical Faculty, Otto-von-Guericke-University Magdeburg, number 145–21).

This study comprises data from six centers:

- Radiology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy;
- Department of Radiology, University of Hacettepe School of Medicine, Ankara, Turkey;
- Department of Radiology and Nuclear Medicine, Otto-von-Guericke University Magdeburg;
- Department of Radiology, University of Health Sciences, Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Radiology;
- Department of Radiology, Mustafa-Kemal-University, Antakya, Turkey;
- Department of Radiology, Istanbul University, Istanbul, Turkey.

In the centers, the data were acquired retrospectively. Inclusion criteria were as follows:

- diagnosis of COVID-19 confirmed by PCR;
- available thoracic CT images without intravenous administration of contrast medium;
- available data regarding the following clinical outcomes: 30-day mortality, need for mechanical ventilation, and admission on an intensive care unit.

Exclusion criteria were as follows:

- cases with missing data regarding the previously-mentioned outcomes;
- CT images after intravenous application of contrast medium;
- missing confirmation of COVID-19 infection by PCR.

The acquired sample comprises 1138 patients. There were 547 women (48.1%) and 591 men (51.9%) with a mean age of 54.5 ± 18.8 years; median age, 55 years; range, 18–84 years. In every case, thoracic CT without intravenous application of contrast medium was performed on different clinical CT scanners or on each center’s CT units.

**Measure of the Pectoralis Musculature on CT**

In every case, the first CT scan of patients after hospital admission was used. In all six centers, measurements were performed by experienced radiologists blinded to the clinical course of patients. The measurements were performed on axial images at the T4 level in the soft tissue window on dedicated workstations. A polygonal region of interest (ROI) was drawn along the contours of the pectoralis major and minor muscles on both sides (Figs 1 and 2). Pectoralis muscle area (PMA) was defined as a sum of the bilateral areas of the pectoralis major and minor muscles. Furthermore, pectoralis muscle density was measured within the ROIs. Pectoralis muscle index (PMI) was calculated as a ratio PMA divided by the patient’s body height square. Additionally, skeletal muscle gauge (SMG) was calculated by multiplying PMI with mean muscle density as reported previously (10).

**Figure 1.** Imaging findings in a 55-year-old woman with COVID-19. Pectoralis muscle area = 14.48 cm², pectoralis muscle density = 28 HU, pectoralis muscle index = 5.19, pectoralis muscle gauge = 145.3. The patient died on the day 19 after admission. (Color version of figure is available online.)

**Figure 2.** Imaging findings in a 61-year-old man with COVID-19. Pectoralis muscle area = 28.17 cm², pectoralis muscle density = 30 HU, pectoralis muscle index = 8.69, pectoralis muscle gauge = 260.7. The patient was discharged in good health. (Color version of figure is available online.)
Statistical Analysis

Statistical analysis was performed using the SPSS package (IBM SPSS Statistics for Windows, version 225.0, Armonk, NY: IBM corporation). Continuous variables were described by mean value, median and standard deviation. Categorical variables were given as relative frequencies. The comparison of pectoralis muscle parameters was performed by Mann-Whitney-U tests and the $p$-values were adjusted for multiple testing (Bonferroni correction). To assess the impact of the pectoralis musculature on clinical outcomes, univariate and multivariable logistic regression models were used to assess the impact of pectoralis muscle on clinical outcomes. Odds ratios were presented together with 95% confidence intervals (95% CI). In all instances, $p$ values < 0.05 were taken to indicate statistical significance.

RESULTS

The estimated values (Mean ± SD) of the pectoralis muscles were as follows: pectoralis muscle area, 28.91 ± 13.60 cm$^2$; skeletal muscle index, 10.85 ± 4.47 cm$^2$/m$^2$; pectoralis muscle density, 35.50 ± 13.77 HU; pectoralis muscle gauge, 401.30 ± 251.87.

Overall, 220 patients (19.33%) were admitted to intensive care unit. Furthermore, in 171 patients (15.03%), mechanical lung ventilation was performed. Finally, 154 patients (13.53%) died within the observation time of 30-day. All investigated muscle values or parameters of pectoralis muscles were lower in the patients with unfavorable courses of COVID-19 (Table 1).

Regression analysis identified that all pectoralis muscle parameters were associated with unfavorable courses (Table 2). Also, all pectoralis muscle parameters were associated with unfavorable courses after adjusting for age and sex (Table 3).

| TABLE 1. Comparison of the Pectoralis Muscle Parameters in Patients With COVID-19 |
|----------------------------------|-----------------|-----------------|--------|
|                                   | No ICU Admission | ICU Admission   | $p$    |
|----------------------------------|-----------------|-----------------|--------|
| Pectoralis muscle area, cm$^2$    | 28.90 ± 14.17   | 25.20 ± 10.09   | <0.001 |
| Pectoralis muscle density, HU     | 37.29 ± 12.98   | 28.03 ± 14.56   | <0.001 |
| Pectoralis muscle index, cm$^2$/m$^2$ | 11.03 ± 4.60  | 9.23 ± 3.54     | <0.001 |
| Pectoralis muscle gauge           | 436.77 ± 252.03 | 274.55 ± 206.89 | <0.001 |

|                                   | No Mechanical Ventilation | Mechanical Ventilation | $p$    |
|----------------------------------|-----------------|-----------------|--------|
| Pectoralis muscle area, cm$^2$    | 29.75 ± 13.95   | 24.15 ± 10.16   | <0.001 |
| Pectoralis muscle density, HU     | 36.91 ± 13.06   | 27.48 ± 15.06   | <0.001 |
| Pectoralis muscle index, cm$^2$/m$^2$ | 11.24 ± 4.53  | 8.86 ± 3.57     | <0.001 |
| Pectoralis muscle gauge           | 428.67 ± 250.47 | 257.50 ± 206.24 | <0.001 |

|                                   | Survivors      | Nonsurvivors    | $p$    |
|----------------------------------|----------------|-----------------|--------|
| Pectoralis muscle area, cm$^2$    | 30.189 ± 13.74 | 20.757 ± 9.13   | <0.001 |
| Pectoralis muscle density, HU     | 36.841 ± 13.15 | 26.929 ± 14.71  | <0.001 |
| Pectoralis muscle index, cm$^2$/m$^2$ | 11.277 ± 4.49 | 8.0365 ± 3.15   | <0.001 |
| Pectoralis muscle gauge           | 428.305 ± 250.02 | 223.505 ± 182.80 | <0.001 |

DISCUSSION

The present study showed at the first time the prognostic role of the pectoralis musculature in COVID-19 based on a large sample in a multicenter setting.

According to the literature, parameters of body composition measured on cross sectional imaging techniques like CT play an important clinical role and are strong predictors for several relevant outcomes in different disorders (11–15). Importantly, muscle measurement is a by-product of cross-sectional imaging and does not need additional investigations. So far, in patients with abdominal trauma, low skeletal muscle mass on CT is significantly associated with longer hospitalization, longer intensive care length of stay, higher cost, higher frequency of mechanical ventilation, longer duration of vasoressor use, and higher incidence of massive transfusion and transfusion-related complications (11). Furthermore, in trauma patients, LSMM increases risk of 30-day mortality, RR = 1.60 CI 95% (1.21–2.13) and risk of 1-year mortality, RR = 3.11 CI 95% (1.94–4.96) (12).

There are numerous large meta-analyses suggesting that LSMM is an essential biomarker in oncology. In short, in lung cancer, LSMM is associated with a shorter overall survival HR = 2.23 CI 95% (1.68–2.94) (13). In head and neck cancer, LSMM is associated with occurrence of severe postoperative complications, OR = 4.79, CI 95% (2.52–9.11), and predicts disease free survival HR = 1.64, CI 95% (1.33–2.03), as well as overall survival, HR = 1.87, CI 95% (1.53–2.29) (14). Finally, LSMM predicts worse overall survival in gastric cancer, HR = 2.12, CI 95% (1.89–2.38) (15). Similar findings are known for pancreatic cancer, colorectal cancer, esophageal cancer, prostatic cancer, and malignant hematological diseases (16–20). In intensive care units, LSMM predicts short-term mortality, HR = 2.78 CI 95% (2.05–3.75) (21).
In COVID-19, data concerning the role of LSMM are mixed (9,22–25). So far, Schiaffino et al. indicates that LSMM is strongly associated with either ICU admission, OR = 4.8, CI 95% (2.7–8.5), \( p < 0.001 \) and mortality, OR = 2.3, CI 95% (1.0–2.9), \( p < 0.027 \) (9). Kim et al. reports that LSMM is associated with prolonged hospital stay in patients with COVID-19 but not with mortality (22). However, other authors do not report significant relationships between LSMM and relevant outcomes in patients with COVID-19 (24,25). For example, according to Moctezuma-Velázquez et al., skeletal muscle index is not associated with negative outcomes, such as in-hospital mortality, need of invasive mechanical ventilation, and intensive care unit admission, in hospitalized patients with COVID-19 (24).

Our results based on the largest cohort to date show that all pectoralis muscle values including muscle area, index, density and gauge are statistically significant higher in survivors vs nonsurvivors. It indicates that patients with more metabolic reserve and predominance of anabolic processes may have a better prognosis. However, according to the regression analysis, the investigated pectoralis muscle parameters cannot discriminate patients with favorable vs unfavorable disease courses. This finding suggests that the status of the pectoralis musculature cannot be used for patients stratifying in COVID-19.

Associations between LSMM and unfavorable courses of COVID-19 are multifactorial. The presence of LSMM may reflect a state of malnutrition and/or catabolism. It is also known that anemia and hypoalbuminemia are associated with low muscle density (26). Furthermore, there are significant interactions between the skeletal musculature and immune system. So far, skeletal muscles release numerous myokines with autocrine, paracrine, and immune effects (27). For instance, interleukin (IL)-15 is a myokine that stimulates proliferation and activation of natural killer cells and CD8+

### TABLE 2. Associations Between Pectoralis Muscle Values and Unfavorable Outcomes in COVID-19 (Univariate Analysis)

| Muscle Parameters                     | OR       | CI95%   | \( p \) Values |
|---------------------------------------|----------|---------|----------------|
| Pectoralis muscle area, cm\(^2\)      | 0.97     | (0.96, 0.98) | <0.001        |
| Pectoralis muscle density, HU          | 0.95     | (0.93, 0.96) | <0.001        |
| Pectoralis muscle index, cm\(^2\)/m\(^2\) | 0.88     | (0.85, 0.92) | <0.001        |
| Pectoralis muscle gauge                | 0.996    | (0.996, 0.997) | <0.001       |

### TABLE 3. Associations Between Pectoralis Muscle Values and Unfavorable Outcomes in COVID-19 (Multivariate Analysis)

| Muscle Parameters                     | OR       | CI95%   | \( p \) Values |
|---------------------------------------|----------|---------|----------------|
| Pectoralis muscle area, cm\(^2\)      | 0.99     | (0.98, 1.007) | 0.391         |
| Pectoralis muscle density, HU          | 0.96     | (0.95, 0.97) | <0.001        |
| Pectoralis muscle index, cm\(^2\)/m\(^2\) | 0.94     | (0.90, 0.99) | <0.001        |
| Pectoralis muscle gauge                | 0.998    | (0.997, 0.999) | <0.001       |

| Muscle Parameters                     | OR       | CI95%   | \( p \) Values |
|---------------------------------------|----------|---------|----------------|
| Pectoralis muscle area, cm\(^2\)      | 0.98     | (0.97, 0.99) | 0.033         |
| Pectoralis muscle density, HU          | 0.96     | (0.94, 0.97) | <0.001        |
| Pectoralis muscle index, cm\(^2\)/m\(^2\) | 0.87     | (0.87, 0.96) | <0.001        |
| Pectoralis muscle gauge                | 0.997    | (0.996, 0.999) | <0.001       |

| Muscle Parameters                     | OR       | CI95%   | \( p \) Values |
|---------------------------------------|----------|---------|----------------|
| Pectoralis muscle area, cm\(^2\)      | 0.96     | (0.94, 0.98) | <0.001        |
| Pectoralis muscle density, HU          | 0.96     | (0.95, 0.98) | <0.001        |
| Pectoralis muscle index, cm\(^2\)/m\(^2\) | 0.86     | (0.80, 0.91) | <0.001        |
| Pectoralis muscle gauge                | 0.996    | (0.995, 0.998) | <0.001       |
T lymphocytes (28). These cells play an essential role in anti-viral immune defense (28). Furthermore, IL 15 induces activation and phagocytosis of neutrophils (29). IL 15 also delays human neutrophil apoptosis (30). Presumably, in patients with reduced muscle quantity and/or quality a smaller number of myokinases is produced.

Notably, different measurements and values for estimation of LSMM in patients with COVID-19 are used. According to the literature, SMI estimation on CT at the level of the third lumbar vertebra (L3) represents a standardized method to quantify the skeletal musculature (31). In patients with COVID-19, often only thoracic CT investigations for the analysis of pulmonary damage are performed. Therefore, the estimation of the standardized SMI values at the L3 level is impossible. Hence, in the previous studies, other vertebral levels for the quantification of the skeletal musculature are proposed, such as thoracic vertebra 5 (32), thoracic vertebra 12 (22,24,33), or lumbar vertebra 1 (34). The pectoralis muscles as surrogate marker is also used (35,36).

The present study has several limitations. Firstly, it is based on retrospective cohorts. Secondly, only patients, who underwent CT investigations without intravenous administration of contrast medium, were included. Thirdly, we did not analyze virus subtypes in our patients. It is well known that several viruses provoke different disease severity. However, to date, it is the largest multicenter cohort and our results represent evidence based data regarding associations between skeletal musculature and clinical outcomes in COVID-19.

In conclusion, in COVID-19, survivors have larger areas and higher index, gauge and density of the pectoralis muscles in comparison to nonsurvivors. However, the analyzed muscle parameters cannot be used for prediction of disease courses.

FUNDING

None.

ACKNOWLEDGMENT

This research was supported by the German Federal Ministry of Education and Research (BMBF) as part of the University Medicine Network (Project RACOON, 01KX2021).

REFERENCES

1. Abate SM, Ahmed Ali S, Mantfardo B, et al. Rate of Intensive Care Unit admission and outcomes among patients with coronavirus: a systematic review and Meta-analysis. PLoS One 2020; 15:e0235653.
2. Hu Y, Sun J, Dai Z, et al. Prevalence and severity of corona virus disease 2019 (COVID-19); a systematic review and meta-analysis. J Clin Virol 2020; 127:104371.
3. Liu B, Spokes P, He W, et al. High risk groups for severe COVID-19 in a whole of population cohort in Australia. BMC Infect Dis 2021; 21:685.
4. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect 2020; 81:e16-e25.
5. Besutti G, Ottone M, Fasano T, et al. The value of computed tomography in assessing the risk of death in COVID-19 patients presenting to the emergency room. Eur Radiol 2021; 1–12.
6. Koch V, Gruenewald LD, Albrecht MH, et al. Lung opacity and coronary artery calcium score: a combined tool for risk stratification and outcome prediction in COVID-19 patients. Acad Radiol 2022; 29:861–870.
7. Salehi S, Abedi A, Balakrishnan S, et al. Coronavirus Disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol 2020; 215:87–93.
8. Meyer HJ, Wiencek A, Surov A. Extrapulmonary CT findings predict inhospital mortality in COVID-19. A systematic review and meta-analysis. Acad Radiol 2022; 29:17–30.
9. Schiaffino S, Albano D, Cozzi A, et al. CT-derived chest muscle metrics for outcome prediction in patients with COVID-19. Radiology 2021; 300: E328–E336.
10. Kardas H, Thomann M, Bar C, et al. Impact of pectoral muscle values on clinical outcomes in patients with severe Covid-19 disease. In Vivo 2022; 36:375–380.
11. Xi F, Tan S, Gao T, Ding W, Sun J, Wei C, Li W, Yu W. Low skeletal muscle mass predicts poor clinical outcomes in patients with abdominal trauma. Nutrition 2021; 89:11228. doi:10.1016/j.nut.2021.112289.
12. Xia W, Barazanchi AWH, MacFater WS, Hill AG. The impact of computed tomography-assessed sarcopenia on outcomes for trauma patients - a systematic review and meta-analysis. Injury 2019; 50:1565–1576.
13. Yang M, Shen Y, Tan L, Li W. Prognostic value of sarcopenia in lung cancer: a systematic review and meta-analysis. Chest 2019; 156:101–111.
14. Surov A, Wiencek A. Low skeletal muscle mass predicts relevant clinical outcomes in head and neck squamous cell carcinoma. A meta analysis. Ther Adv Med Oncol 2021; 13:1758539211008844.
15. Kamarajah SK, Bunded J, Tan BHL. Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2019; 22:10–22.
16. Meyer HJ, Wiencek A, Surov A. CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: a systematic review and meta-analysis. Urol Oncol 2022; 40:e103.e9–103.e16. S1078-1439(21)00368-9.
17. Deng HY, Zha P, Peng L, Hou L, Huang KL, Li XY. Preoperative sarcopenia is a predictor of poor prognosis of esophageal cancer after esophagectomy: a comprehensive systematic review and meta-analysis. Dis Esophagus 2019; 32. doi:10.1093/dote/doy115.
18. Trejo-Avila M, Bozada-Gutierrez K, Valenzuela-Salazar C, Herrera-Esquível J, Moreno-Portillo M. Sarcopenia predicts worse postoperative outcomes and decreased survival rates in patients with colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 2021; 36:1077–1096.
19. Bunded J, Kamarajah SK, Roberts KJ. Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis. HPB (Oxford) 2019; 21:1603–1612.
20. Surov A, Wiencek A. Sarcopenia predicts overall survival in patients with malignant hematological diseases: a meta-analysis. Clin Nutr 2021; 40:1155–1160.
21. Meyer HJ, Wiencek A, Surov A. Computed tomography-defined low skeletal muscle mass as a prognostic marker for short-term mortality in critically ill patients: a systematic review and meta-analysis. Nutrition 2021; 91-92:111417.
22. Kim JW, Yoon JS, Kim EJ, et al. Prognostic implication of baseline sarcopenia for length of hospital stay and survival in patients with coronavirus Disease2019. J Gerontol A Biol Sci Med Sci 2021; 76:e110–e116.
23. Viddeler AR, Raaphorst J, Min M, et al. Intramuscular adipose tissue at level Th12 is associated with survival in COVID-19. J Cachexia Sarcopenia Muscle 2021; 12:823–827.
24. Mociezuma-Velazquez P, Miranda-Zazueta G, Ortiz-Brizuela E, et al. Low Thoracic Skeletal Muscle Area Is Not Associated With Negative Outcomes in Patients With COVID-19. Am J Phys Med Rehabil 2021; 100:413–418.
25. Molwitz I, Ozga AK, Gerdes L, et al. Prediction of abdominal CT body composition parameters by thoracic measurements as a new approach to detect sarcopenia in a COVID-19 cohort. Sci Rep 2022; 12:6443.
26. Fragala MS, Kenny AM, Kuchel GA. Muscle quality in aging: a multi-dimensional approach to muscle functioning with applications for treatment. Sport Med 2015; 45:641–658.
27. Nelke C, Dziewas R, Minnervu J, et al. Skeletal muscle as potential central link between sarcopenia and immune senescence. EBioMedicine 2019; 49:381–388.
28. Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015; 33:74–82.

29. Girard D, Paquet ME, Paquin R, et al. Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15. Blood 1996; 88:3176–3184.

30. Bouchard A, Ratthe C, Girard D. Interleukin-15 delays human neutrophil apoptosis by intracellular events and not via extracellular factors: role of Mcl-1 and decreased activity of caspase-3 and caspase-8. J Leukoc Biol 2004; 75:893–900.

31. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48:601.

32. Poros B, Becker-Pennrich AS, Sabel B, et al. Anthropometric analysis of body habitus and outcomes in critically ill COVID-19 patients. Obes Med 2021; 25:100358.

33. Feng Z, Zhao H, Kang W, et al. Association of paraspinal muscle measurements on chest computed tomography with clinical outcomes in patients with severe coronavirus disease 2019. J Gerontol A Biol Sci Med Sci 2021; 76:e78–e84.

34. Petersen A, Bressem K, Albrecht J, et al. The role of visceral adiposity in the severity of COVID-19: Highlights from a uncenter cross-sectional pilot study in Germany. Metabolism 2020; 110:154317.

35. Hocaoglu E, Ors S, Yildiz O, Inci E. Correlation of pectoralis muscle volume and density with severity of COVID-19 pneumonia in adults. Acad Radiol 2021; 28:166–172.

36. Ufuk F, Demirci M, Sagtas E, et al. The prognostic value of pneumonia severity score and pectoralis muscle Area on chest CT in adult COVID-19 patients. Eur J Radiol 2020; 131:109271.